Related Experiment Video
Updated: Aug 17, 2025
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Renal Thrombotic Microangiopathy: A Review
Dominique Suzanne Genest1, Christopher J Patriquin2, Christoph Licht3
1Division of Nephrology, University Health Network, Toronto, Ontario, Canada; Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Abstract:
Thrombotic microangiopathy (TMA), a pathological lesion observed in a wide spectrum of diseases, is triggered by endothelial injury and/or dysfunction. Although TMA lesions are often accompanied by clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and ischemic end-organ injury, renal-limited forms of TMA are not infrequently encountered in clinical practice. The presence of renal-limited manifestations can be diagnostically challenging, often delaying the initiation of targeted therapy. Prompt investigation and empirical treatment of TMA is warranted to reduce associated morbidity and mortality. Major advances have been made with respect to the pathophysiology of primary TMA entities, with the subsequent development of novel diagnostic tools and lifesaving therapies for diseases like thrombotic thrombocytopenic purpura and complement-mediated TMA. This article will review the clinical presentation and pathologic hallmarks of TMA involving the kidney, and the disease-specific mechanisms that contribute to the endothelial injury that characterizes TMA lesions. Diagnostic approach and both empirical and disease-specific treatment strategies will be discussed, along with the potential role for emerging targeted disease-specific therapies.
Insights
Thrombotic microangiopathy (TMA) involves kidney damage and can be hard to diagnose. Early treatment is crucial for better outcomes in patients with this condition.
Area of Science:
- Nephrology
- Hematology
- Pathology
Background:
- Thrombotic microangiopathy (TMA) is characterized by endothelial injury, leading to microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
- Renal-limited TMA presents diagnostic challenges, potentially delaying critical interventions.
- Advances in understanding TMA pathophysiology have led to new diagnostic tools and therapies for conditions like thrombotic thrombocytopenic purpura and complement-mediated TMA.
Purpose of the Study:
- To review the clinical and pathological features of kidney-involved TMA.
- To discuss disease-specific mechanisms underlying endothelial injury in TMA.
- To outline diagnostic approaches and treatment strategies, including emerging therapies.
Main Methods:
- Review of clinical presentations and pathological hallmarks of renal TMA.
- Analysis of disease-specific mechanisms contributing to endothelial injury.
- Discussion of diagnostic criteria and therapeutic interventions.
Main Results:
- Renal-limited TMA can be challenging to diagnose, impacting timely treatment initiation.
- Understanding TMA pathophysiology is key to developing targeted therapies.
- Novel diagnostic tools and life-saving treatments are available for specific TMA entities.
Conclusions:
- Prompt diagnosis and empirical treatment of TMA are essential to reduce morbidity and mortality.
- This review covers diagnostic strategies and therapeutic options for TMA affecting the kidney.
- Emerging targeted therapies hold promise for managing TMA.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis I: Introduction
01:30Venous Thrombosis IV: Nursing Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:16Clot Retraction and Fibrinolysis